Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-039-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.68 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
5 analysts have issued twelve-month price targets for CELYAD SA/ADR's stock. Their forecasts range from $41.00 to $52.00. On average, they expect CELYAD SA/ADR's share price to reach $46.50 in the next twelve months. This suggests a possible upside of 142.3% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.
What are Wall Street analysts saying about CELYAD SA/ADR stock?
Here are some recent quotes from research analysts about CELYAD SA/ADR stock:
- 1. William Blair analysts commented, "We believe the data update represents an inflection point for the company and the cell therapy space because: 1) the presentation will provide a novel perspective on an allogeneic (CY AD-101) vs. autologous (CY AD-01) approach as both candidates use the same NKG2D CAR construct to target in the same indication (metastatic colorectal cancer [mCRC]); 2) it offers the ability to see data from both neoadjuvant and refractory patients; and 3) it will be the first clinical data shown with a non-gene-edited, non-CD-19 allogeneic CAR-T . Lastly , we note that bluebird bio (BLUE $132.49; Outperform) recently presented a NKG2D CAR-T poster at ASGCT (likely its AML collaboration with Seattle Children’s), which we view as validation of Celyad’s approach." (5/13/2019)
- 2. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (1/29/2019)
- 3. HC Wainwright analysts commented, "We base our $46 price target on probability-adjusted revenue forecasts for CYAD-01 in r/r AML and third line metastatic CRC. We use the net present value of our revenue forecast through 2026, apply a 25% POS for AML and 20% POS for CRC, a 4x price/sales multiple. We include our year-end 2018 estimated fully diluted net cash of $4.39/share (assuming €1.00 = $1.15) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x." (11/21/2018)
Has CELYAD SA/ADR been receiving favorable news coverage?
News stories about CYAD stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CELYAD SA/ADR earned a news impact score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Cara Therapeutics (CARA), ArQule (ARQL), Y-mAbs Therapeutics (YMAB), ChemoCentryx (CCXI), Arvinas (ARVN), Vectura Group (VEGPF), Aptorum Group (APM), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI), Lexicon Pharmaceuticals (LXRX), Emisphere Technologies (EMIS), Advanz Pharma (CXRXF), Akebia Therapeutics (AKBA), Organogenesis (ORGO) and Crinetics Pharmaceuticals (CRNX).
What other stocks do shareholders of CELYAD SA/ADR own?
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)
- Mr. Filippo Joseph Petti, CEO & Interim CFO
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 44)
- Nicolas Van Hoecke, Director of Investor Relations & Communications
- Mr. Philippe Dechamps, Chief Legal Officer (Age 49)
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Who are CELYAD SA/ADR's major shareholders?
CELYAD SA/ADR's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (6.81%), Morgan Stanley (0.10%) and Wells Fargo & Company MN (0.08%).
Which major investors are buying CELYAD SA/ADR stock?
CYAD stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley and Wells Fargo & Company MN.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $19.19.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $189.41 million and generates $3.68 million in revenue each year. The company earns $-44,200,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis.
What is CELYAD SA/ADR's official website?
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
